Intrommune Therapeutics, Inc. is excited to announce the publication of a its Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) study evaluating the safety, tolerability, and adherence of a ...
The Company’s 2025 financial guidance reflects its evolution to a fully integrated commercial-stage biotechnology company independently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback